APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lung Cancer Diagnostic And Screening

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lung Cancer Diagnostic And Screening Market Outlook and Growth Opportunities 2026

5 March 2026204 pages

Choose your research edition.

Industry ResearchLung Cancer Diagnostic And Screening Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Lung Cancer Diagnostic And Screening Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Lung Cancer Diagnostic And Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lung Cancer Diagnostic And Screening Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Lung Cancer Diagnostic And Screening Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Lung Cancer Diagnostic And Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lung Cancer Diagnostic And Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lung Cancer Diagnostic And Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lung Cancer Diagnostic And Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lung Cancer Diagnostic And Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lung Cancer Diagnostic And Screening market include Pfizer, F.Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific, AstraZeneca Plc, Abbott Laboratories, Medtronic Plc, Danaher Corporation and Siemens Healthcare GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Lung Cancer Diagnostic And Screening market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lung Cancer Diagnostic And Screening and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lung Cancer Diagnostic And Screening revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Lung Cancer Diagnostic And Screening market.

Lung Cancer Diagnostic And Screening Segment by Company

Pfizer

F.Hoffmann-La Roche AG

Bristol-Myers Squibb Company

Thermo Fisher Scientific

AstraZeneca Plc

Abbott Laboratories

Medtronic Plc

Danaher Corporation

Siemens Healthcare GmbH

FUJIFILM Corporation

KoninklijikePhilips N.V.

GE Healthcare Bio Sciences AB

Quest Diagnostics lIncorporated

Agilent Technologies lnc

Qiagen Inc.

Myriad Genetic Laboratories Inc.

NeoGenomics Laboratories Inc

Canon MedicalSystems Corporation

Eon Health Inc

Lung Cancer Diagnostic And Screening Segment by Type

Instrument

Consumables and Accessories

Lung Cancer Diagnostic And Screening Segment by Application

Hospital

Independent Diagnostic Laboratory

Lung Cancer Diagnostic And Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lung Cancer Diagnostic And Screening status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Lung Cancer Diagnostic And Screening key companies, revenue, market share, and recent developments.

3. To split the Lung Cancer Diagnostic And Screening breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Lung Cancer Diagnostic And Screening market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lung Cancer Diagnostic And Screening significant trends, drivers, influence factors in global and regions.

6. To analyze Lung Cancer Diagnostic And Screening competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Diagnostic And Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Diagnostic And Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Diagnostic And Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lung Cancer Diagnostic And Screening industry.

Chapter 3: Detailed analysis of Lung Cancer Diagnostic And Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Lung Cancer Diagnostic And Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Lung Cancer Diagnostic And Screening in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lung Cancer Diagnostic And Screening Industry Trends Table 2. Lung Cancer Diagnostic And Screening Industry Drivers Table 3. Lung Cancer Diagnostic And Screening Industry Opportunities and Challenges Table 4. Lung Cancer Diagnostic And Screening Industry Restraints Table 5. Global Lung Cancer Diagnostic And Screening Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lung Cancer Diagnostic And Screening Revenue Share by Company (2021-2026) Table 7. Global Lung Cancer Diagnostic And Screening Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Lung Cancer Diagnostic And Screening Key Company Manufacturing Base & Headquarters Table 9. Global Lung Cancer Diagnostic And Screening Company, Product Type & Application Table 10. Global Lung Cancer Diagnostic And Screening Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Lung Cancer Diagnostic And Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Instrument Table 15. Significant Companies of Consumables and Accessories Table 16. Global Lung Cancer Diagnostic And Screening Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Lung Cancer Diagnostic And Screening Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Lung Cancer Diagnostic And Screening Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Lung Cancer Diagnostic And Screening Sales Value Share by Type (2021-2026) Table 20. Global Lung Cancer Diagnostic And Screening Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Independent Diagnostic Laboratory Table 23. Global Lung Cancer Diagnostic And Screening Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Lung Cancer Diagnostic And Screening Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Lung Cancer Diagnostic And Screening Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Lung Cancer Diagnostic And Screening Sales Value Share by Application (2021-2026) Table 27. Global Lung Cancer Diagnostic And Screening Sales Value Share by Application (2027-2032) Table 28. Global Lung Cancer Diagnostic And Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Lung Cancer Diagnostic And Screening Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Lung Cancer Diagnostic And Screening Sales Value Share by Region (2021-2026) Table 31. Global Lung Cancer Diagnostic And Screening Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Lung Cancer Diagnostic And Screening Sales Value Share by Region (2027-2032) Table 33. Global Lung Cancer Diagnostic And Screening Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Lung Cancer Diagnostic And Screening Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Lung Cancer Diagnostic And Screening Sales Value Market Share by Country (2021-2026) Table 36. Global Lung Cancer Diagnostic And Screening Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Lung Cancer Diagnostic And Screening Sales Value Market Share by Country (2027-2032) Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Pfizer Lung Cancer Diagnostic And Screening Product Portfolio Table 42. Pfizer Recent Development Table 43. F.Hoffmann-La Roche AG Company Information Table 44. F.Hoffmann-La Roche AG Business Overview Table 45. F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Product Portfolio Table 47. F.Hoffmann-La Roche AG Recent Development Table 48. Bristol-Myers Squibb Company Company Information Table 49. Bristol-Myers Squibb Company Business Overview Table 50. Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Product Portfolio Table 52. Bristol-Myers Squibb Company Recent Development Table 53. Thermo Fisher Scientific Company Information Table 54. Thermo Fisher Scientific Business Overview Table 55. Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Product Portfolio Table 57. Thermo Fisher Scientific Recent Development Table 58. AstraZeneca Plc Company Information Table 59. AstraZeneca Plc Business Overview Table 60. AstraZeneca Plc Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. AstraZeneca Plc Lung Cancer Diagnostic And Screening Product Portfolio Table 62. AstraZeneca Plc Recent Development Table 63. Abbott Laboratories Company Information Table 64. Abbott Laboratories Business Overview Table 65. Abbott Laboratories Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Abbott Laboratories Lung Cancer Diagnostic And Screening Product Portfolio Table 67. Abbott Laboratories Recent Development Table 68. Medtronic Plc Company Information Table 69. Medtronic Plc Business Overview Table 70. Medtronic Plc Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Medtronic Plc Lung Cancer Diagnostic And Screening Product Portfolio Table 72. Medtronic Plc Recent Development Table 73. Danaher Corporation Company Information Table 74. Danaher Corporation Business Overview Table 75. Danaher Corporation Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Danaher Corporation Lung Cancer Diagnostic And Screening Product Portfolio Table 77. Danaher Corporation Recent Development Table 78. Siemens Healthcare GmbH Company Information Table 79. Siemens Healthcare GmbH Business Overview Table 80. Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Product Portfolio Table 82. Siemens Healthcare GmbH Recent Development Table 83. FUJIFILM Corporation Company Information Table 84. FUJIFILM Corporation Business Overview Table 85. FUJIFILM Corporation Lung Cancer Diagnostic And Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. FUJIFILM Corporation Lung Cancer Diagnostic And Screening Product Portfolio Table 87. FUJIFILM Corporation Recent Development Table 88. KoninklijikePhilips N.V. Company Information Table 89. KoninklijikePhilips N.V. Business Overview Table 90. KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Product Portfolio Table 92. KoninklijikePhilips N.V. Recent Development Table 93. GE Healthcare Bio Sciences AB Company Information Table 94. GE Healthcare Bio Sciences AB Business Overview Table 95. GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Product Portfolio Table 97. GE Healthcare Bio Sciences AB Recent Development Table 98. Quest Diagnostics lIncorporated Company Information Table 99. Quest Diagnostics lIncorporated Business Overview Table 100. Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Product Portfolio Table 102. Quest Diagnostics lIncorporated Recent Development Table 103. Agilent Technologies lnc Company Information Table 104. Agilent Technologies lnc Business Overview Table 105. Agilent Technologies lnc Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Agilent Technologies lnc Lung Cancer Diagnostic And Screening Product Portfolio Table 107. Agilent Technologies lnc Recent Development Table 108. Qiagen Inc. Company Information Table 109. Qiagen Inc. Business Overview Table 110. Qiagen Inc. Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Qiagen Inc. Lung Cancer Diagnostic And Screening Product Portfolio Table 112. Qiagen Inc. Recent Development Table 113. Myriad Genetic Laboratories Inc. Company Information Table 114. Myriad Genetic Laboratories Inc. Business Overview Table 115. Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Product Portfolio Table 117. Myriad Genetic Laboratories Inc. Recent Development Table 118. NeoGenomics Laboratories Inc Company Information Table 119. NeoGenomics Laboratories Inc Business Overview Table 120. NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Product Portfolio Table 122. NeoGenomics Laboratories Inc Recent Development Table 123. Canon MedicalSystems Corporation Company Information Table 124. Canon MedicalSystems Corporation Business Overview Table 125. Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Product Portfolio Table 127. Canon MedicalSystems Corporation Recent Development Table 128. Eon Health Inc Company Information Table 129. Eon Health Inc Business Overview Table 130. Eon Health Inc Lung Cancer Diagnostic And Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Eon Health Inc Lung Cancer Diagnostic And Screening Product Portfolio Table 132. Eon Health Inc Recent Development Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Lung Cancer Diagnostic And Screening Product Image Figure 2. Global Lung Cancer Diagnostic And Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lung Cancer Diagnostic And Screening Market Size (2021-2032) & (US$ Million) Figure 4. Global Lung Cancer Diagnostic And Screening Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Instrument Image Figure 8. Consumables and Accessories Image Figure 9. Global Lung Cancer Diagnostic And Screening Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Lung Cancer Diagnostic And Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Lung Cancer Diagnostic And Screening Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Independent Diagnostic Laboratory Image Figure 14. Global Lung Cancer Diagnostic And Screening Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Lung Cancer Diagnostic And Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Lung Cancer Diagnostic And Screening Sales Value Share by Application (2021-2032) Figure 17. Global Lung Cancer Diagnostic And Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Lung Cancer Diagnostic And Screening Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Lung Cancer Diagnostic And Screening Sales Value (2021-2032) & (US$ Million) Figure 20. North America Lung Cancer Diagnostic And Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Lung Cancer Diagnostic And Screening Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Lung Cancer Diagnostic And Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Lung Cancer Diagnostic And Screening Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Lung Cancer Diagnostic And Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Lung Cancer Diagnostic And Screening Sales Value (2021-2032) & (US$ Million) Figure 26. South America Lung Cancer Diagnostic And Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Lung Cancer Diagnostic And Screening Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Lung Cancer Diagnostic And Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Instrument
  • Consumables and Accessories
Applications
  • Hospital
  • Independent Diagnostic Laboratory
Companies covered
  • Pfizer
  • F.Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Thermo Fisher Scientific
  • AstraZeneca Plc
  • Abbott Laboratories
  • Medtronic Plc
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • FUJIFILM Corporation
  • KoninklijikePhilips N.V.
  • GE Healthcare Bio Sciences AB
  • Quest Diagnostics lIncorporated
  • Agilent Technologies lnc
  • Qiagen Inc.
  • Myriad Genetic Laboratories Inc.
  • NeoGenomics Laboratories Inc
  • Canon MedicalSystems Corporation
  • Eon Health Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lung Cancer Diagnostic And Screening Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lung Cancer Diagnostic And Screening Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Lung Cancer Diagnostic And Screening Market Dynamics
  1. 2.1 Lung Cancer Diagnostic And Screening Industry Trends
  2. 2.2 Lung Cancer Diagnostic And Screening Industry Drivers
  3. 2.3 Lung Cancer Diagnostic And Screening Industry Opportunities and Challenges
  4. 2.4 Lung Cancer Diagnostic And Screening Industry Restraints
3 Lung Cancer Diagnostic And Screening Market by Company
  1. 3.1 Global Lung Cancer Diagnostic And Screening Company Revenue Ranking in 2025
  2. 3.2 Global Lung Cancer Diagnostic And Screening Revenue by Company (2021-2026)
  3. 3.3 Global Lung Cancer Diagnostic And Screening Company Ranking (2024-2026)
  4. 3.4 Global Lung Cancer Diagnostic And Screening Company Manufacturing Base and Headquarters
  5. 3.5 Global Lung Cancer Diagnostic And Screening Company Product Type and Application
  6. 3.6 Global Lung Cancer Diagnostic And Screening Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Lung Cancer Diagnostic And Screening Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Lung Cancer Diagnostic And Screening Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Lung Cancer Diagnostic And Screening Market by Type
  1. 4.1 Lung Cancer Diagnostic And Screening Type Introduction
  2. 4.1.1 Instrument
  3. 4.1.2 Consumables and Accessories
  4. 4.2 Global Lung Cancer Diagnostic And Screening Sales Value by Type
  5. 4.2.1 Global Lung Cancer Diagnostic And Screening Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Lung Cancer Diagnostic And Screening Sales Value by Type (2021-2032)
  7. 4.2.3 Global Lung Cancer Diagnostic And Screening Sales Value Share by Type (2021-2032)
5 Lung Cancer Diagnostic And Screening Market by Application
  1. 5.1 Lung Cancer Diagnostic And Screening Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Independent Diagnostic Laboratory
  4. 5.2 Global Lung Cancer Diagnostic And Screening Sales Value by Application
  5. 5.2.1 Global Lung Cancer Diagnostic And Screening Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Lung Cancer Diagnostic And Screening Sales Value by Application (2021-2032)
  7. 5.2.3 Global Lung Cancer Diagnostic And Screening Sales Value Share by Application (2021-2032)
6 Lung Cancer Diagnostic And Screening Regional Value Analysis
  1. 6.1 Global Lung Cancer Diagnostic And Screening Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lung Cancer Diagnostic And Screening Sales Value by Region (2021-2032)
  3. 6.2.1 Global Lung Cancer Diagnostic And Screening Sales Value by Region: 2021-2026
  4. 6.2.2 Global Lung Cancer Diagnostic And Screening Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lung Cancer Diagnostic And Screening Sales Value (2021-2032)
  7. 6.3.2 North America Lung Cancer Diagnostic And Screening Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Lung Cancer Diagnostic And Screening Sales Value (2021-2032)
  10. 6.4.2 Europe Lung Cancer Diagnostic And Screening Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Lung Cancer Diagnostic And Screening Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Lung Cancer Diagnostic And Screening Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Lung Cancer Diagnostic And Screening Sales Value (2021-2032)
  16. 6.6.2 South America Lung Cancer Diagnostic And Screening Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Lung Cancer Diagnostic And Screening Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Lung Cancer Diagnostic And Screening Sales Value Share by Country, 2025 VS 2032
7 Lung Cancer Diagnostic And Screening Country-level Value Analysis
  1. 7.1 Global Lung Cancer Diagnostic And Screening Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lung Cancer Diagnostic And Screening Sales Value by Country (2021-2032)
  3. 7.2.1 Global Lung Cancer Diagnostic And Screening Sales Value by Country (2021-2026)
  4. 7.2.2 Global Lung Cancer Diagnostic And Screening Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Lung Cancer Diagnostic And Screening Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Lung Cancer Diagnostic And Screening Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Lung Cancer Diagnostic And Screening Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Lung Cancer Diagnostic And Screening Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 F.Hoffmann-La Roche AG
  8. 8.2.1 F.Hoffmann-La Roche AG Company Information
  9. 8.2.2 F.Hoffmann-La Roche AG Business Overview
  10. 8.2.3 F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  11. 8.2.4 F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Product Portfolio
  12. 8.2.5 F.Hoffmann-La Roche AG Recent Developments
  13. 8.3 Bristol-Myers Squibb Company
  14. 8.3.1 Bristol-Myers Squibb Company Company Information
  15. 8.3.2 Bristol-Myers Squibb Company Business Overview
  16. 8.3.3 Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 8.4 Thermo Fisher Scientific
  20. 8.4.1 Thermo Fisher Scientific Company Information
  21. 8.4.2 Thermo Fisher Scientific Business Overview
  22. 8.4.3 Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Product Portfolio
  24. 8.4.5 Thermo Fisher Scientific Recent Developments
  25. 8.5 AstraZeneca Plc
  26. 8.5.1 AstraZeneca Plc Company Information
  27. 8.5.2 AstraZeneca Plc Business Overview
  28. 8.5.3 AstraZeneca Plc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Plc Lung Cancer Diagnostic And Screening Product Portfolio
  30. 8.5.5 AstraZeneca Plc Recent Developments
  31. 8.6 Abbott Laboratories
  32. 8.6.1 Abbott Laboratories Company Information
  33. 8.6.2 Abbott Laboratories Business Overview
  34. 8.6.3 Abbott Laboratories Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Abbott Laboratories Lung Cancer Diagnostic And Screening Product Portfolio
  36. 8.6.5 Abbott Laboratories Recent Developments
  37. 8.7 Medtronic Plc
  38. 8.7.1 Medtronic Plc Company Information
  39. 8.7.2 Medtronic Plc Business Overview
  40. 8.7.3 Medtronic Plc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Medtronic Plc Lung Cancer Diagnostic And Screening Product Portfolio
  42. 8.7.5 Medtronic Plc Recent Developments
  43. 8.8 Danaher Corporation
  44. 8.8.1 Danaher Corporation Company Information
  45. 8.8.2 Danaher Corporation Business Overview
  46. 8.8.3 Danaher Corporation Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Danaher Corporation Lung Cancer Diagnostic And Screening Product Portfolio
  48. 8.8.5 Danaher Corporation Recent Developments
  49. 8.9 Siemens Healthcare GmbH
  50. 8.9.1 Siemens Healthcare GmbH Company Information
  51. 8.9.2 Siemens Healthcare GmbH Business Overview
  52. 8.9.3 Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Product Portfolio
  54. 8.9.5 Siemens Healthcare GmbH Recent Developments
  55. 8.10 FUJIFILM Corporation
  56. 8.10.1 FUJIFILM Corporation Company Information
  57. 8.10.2 FUJIFILM Corporation Business Overview
  58. 8.10.3 FUJIFILM Corporation Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  59. 8.10.4 FUJIFILM Corporation Lung Cancer Diagnostic And Screening Product Portfolio
  60. 8.10.5 FUJIFILM Corporation Recent Developments
  61. 8.11 KoninklijikePhilips N.V.
  62. 8.11.1 KoninklijikePhilips N.V. Company Information
  63. 8.11.2 KoninklijikePhilips N.V. Business Overview
  64. 8.11.3 KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  65. 8.11.4 KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Product Portfolio
  66. 8.11.5 KoninklijikePhilips N.V. Recent Developments
  67. 8.12 GE Healthcare Bio Sciences AB
  68. 8.12.1 GE Healthcare Bio Sciences AB Company Information
  69. 8.12.2 GE Healthcare Bio Sciences AB Business Overview
  70. 8.12.3 GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  71. 8.12.4 GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Product Portfolio
  72. 8.12.5 GE Healthcare Bio Sciences AB Recent Developments
  73. 8.13 Quest Diagnostics lIncorporated
  74. 8.13.1 Quest Diagnostics lIncorporated Company Information
  75. 8.13.2 Quest Diagnostics lIncorporated Business Overview
  76. 8.13.3 Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Product Portfolio
  78. 8.13.5 Quest Diagnostics lIncorporated Recent Developments
  79. 8.14 Agilent Technologies lnc
  80. 8.14.1 Agilent Technologies lnc Company Information
  81. 8.14.2 Agilent Technologies lnc Business Overview
  82. 8.14.3 Agilent Technologies lnc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Agilent Technologies lnc Lung Cancer Diagnostic And Screening Product Portfolio
  84. 8.14.5 Agilent Technologies lnc Recent Developments
  85. 8.15 Qiagen Inc.
  86. 8.15.1 Qiagen Inc. Company Information
  87. 8.15.2 Qiagen Inc. Business Overview
  88. 8.15.3 Qiagen Inc. Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Qiagen Inc. Lung Cancer Diagnostic And Screening Product Portfolio
  90. 8.15.5 Qiagen Inc. Recent Developments
  91. 8.16 Myriad Genetic Laboratories Inc.
  92. 8.16.1 Myriad Genetic Laboratories Inc. Company Information
  93. 8.16.2 Myriad Genetic Laboratories Inc. Business Overview
  94. 8.16.3 Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Product Portfolio
  96. 8.16.5 Myriad Genetic Laboratories Inc. Recent Developments
  97. 8.17 NeoGenomics Laboratories Inc
  98. 8.17.1 NeoGenomics Laboratories Inc Company Information
  99. 8.17.2 NeoGenomics Laboratories Inc Business Overview
  100. 8.17.3 NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  101. 8.17.4 NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Product Portfolio
  102. 8.17.5 NeoGenomics Laboratories Inc Recent Developments
  103. 8.18 Canon MedicalSystems Corporation
  104. 8.18.1 Canon MedicalSystems Corporation Company Information
  105. 8.18.2 Canon MedicalSystems Corporation Business Overview
  106. 8.18.3 Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Product Portfolio
  108. 8.18.5 Canon MedicalSystems Corporation Recent Developments
  109. 8.19 Eon Health Inc
  110. 8.19.1 Eon Health Inc Company Information
  111. 8.19.2 Eon Health Inc Business Overview
  112. 8.19.3 Eon Health Inc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Eon Health Inc Lung Cancer Diagnostic And Screening Product Portfolio
  114. 8.19.5 Eon Health Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst